Braves acquire infielder Paul Janish from Reds

5 Comments

The injury-riddled Braves have secured some insurance for the shortstop position.

Mark Bowman of MLB.com confirms that the Braves have acquired infielder Paul Janish from Reds in exchange for minor league right-hander Todd Redmond. David O’Brien of the Atlanta Journal-Constitution notes that he’s expected to join the Braves tomorrow.

The Braves have been on the lookout for help ever since Andrelton Simmons fractured his right pinkie finger on Sunday. The need became even more urgent after Jack Wilson dislocated the middle joint of his right pinkie finger and Martin Prado was forced to fill in at shortstop. The Braves have called up Tyler Pastornicky, but Prado is back at shortstop again this afternoon against the Mets.

Janish is highly-regarded for his defense, but he owns a lowly .221/.289/.302 batting line and a .591 OPS over 975 plate appearances in the big leagues, all with the Reds. The 29-year-old has played exclusively with Triple-A Louisville this season, compiling a .237/.332/.391 batting line and .722 OPS in 49 games played.

Redmond has a 3.57 ERA over parts of eight seasons in the minors, but he’s been stuck at Triple-A Gwinnett since the 2009 season. He’s 27 years old and has never been considered a top prospect despite solid results, so he’ll presumably function as organizational depth with Cincinnati.

Mets sign Matt Kemp to minor league deal

Matt Kemp
Getty Images
2 Comments

The Mets have had a lot of injuries in their outfield. How many? So many that they’re bringing in Matt Kemp, who they just signed on a minor league deal. Hey, why not? He’s functionally free.

Kemp was released by the Reds earlier this month after batting just .200/.210/.283 over 62 plate appearances. While he was a pretty useful player for the first half of the 2018 season for the Dodgers, the odds of him making major contributions to the Mets this year are probably about the same odds there were on Adrián González making an impact when the Mets signed him last year. But again: what’s the harm?